Gain­ing steam in PD-1/L1 race, Roche re­ports pos­i­tive PhI­II OS da­ta on Tecen­triq com­bo in NSCLC

Roche trot­ted out some ear­ly OS da­ta Mon­day morn­ing from its com­bo study of Tecen­triq in lung can­cer, re­port­ing that the com­bo met its co-pri­ma­ry end­point and helped pa­tients live longer.

The da­ta will back up the com­pa­ny’s up­com­ing bid for ap­proval of the drug com­bo as a front-line ther­a­py, mak­ing Roche a stronger con­tender among ri­vals Bris­tol-My­ers Squibb and Mer­ck as the PD-1/L1 mar­ket leader war wages on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER